Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Mullen

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Methods in Molecular Medicine|November 25, 2003
Flow cytometric DNA analysis of human cancer cell linesPeter Mullen
Methods in Molecular Medicine|November 25, 2003
PARP cleavage as a means of assessing apoptosisPeter Mullen
Methods in Molecular Medicine|November 25, 2003
The use of Matrigel to facilitate the establishment of human cancer cell lines as xenograftsPeter Mullen
Expert Opinion on Biological Therapy|May 15, 2010
Pertuzumab for the treatment of ovarian cancerSimon P Langdon, Dana Faratian, Yoko Nagumo, et al.
Molecules (Basel, Switzerland)|October 14, 2022
Objective Supervised Machine Learning-Based Classification and Inference of Biological Neuronal NetworksMichael Taynnan Barros, Harun Siljak, Peter Mullen, et al.
Molecular Cancer Therapeutics|January 24, 2007
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalingPeter Mullen, David A Cameron, Max Hasmann, et al.
International Journal of Cancer|September 27, 2005
Comparison of strategies targeting Raf-1 mRNA in ovarian cancerPeter Mullen, Fiona McPhillips, Brett P Monia, et al.
Plos One|September 16, 2025
A phosphoramidate modification of FUDR, NUC-3373, causes DNA damage and DAMPs release from colorectal cancer cells, potentiating lymphocyte-induced cell deathOliver J Read, Jennifer Bré, Ying Zhang, et al.
Cellular Signalling|October 15, 2011
Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibitionAlexey Goltsov, Dana Faratian, Simon P Langdon, et al.
Molecular Cancer Research : MCR|September 10, 2009
Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivityYoko Nagumo, Dana Faratian, Peter Mullen, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Methods in Molecular Medicine|November 25, 2003
Flow cytometric DNA analysis of human cancer cell linesPeter Mullen
Methods in Molecular Medicine|November 25, 2003
PARP cleavage as a means of assessing apoptosisPeter Mullen
Methods in Molecular Medicine|November 25, 2003
The use of Matrigel to facilitate the establishment of human cancer cell lines as xenograftsPeter Mullen
Expert Opinion on Biological Therapy|May 15, 2010
Pertuzumab for the treatment of ovarian cancerSimon P Langdon, Dana Faratian, Yoko Nagumo, et al.
Molecules (Basel, Switzerland)|October 14, 2022
Objective Supervised Machine Learning-Based Classification and Inference of Biological Neuronal NetworksMichael Taynnan Barros, Harun Siljak, Peter Mullen, et al.
Molecular Cancer Therapeutics|January 24, 2007
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalingPeter Mullen, David A Cameron, Max Hasmann, et al.
International Journal of Cancer|September 27, 2005
Comparison of strategies targeting Raf-1 mRNA in ovarian cancerPeter Mullen, Fiona McPhillips, Brett P Monia, et al.
Plos One|September 16, 2025
A phosphoramidate modification of FUDR, NUC-3373, causes DNA damage and DAMPs release from colorectal cancer cells, potentiating lymphocyte-induced cell deathOliver J Read, Jennifer Bré, Ying Zhang, et al.
Cellular Signalling|October 15, 2011
Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibitionAlexey Goltsov, Dana Faratian, Simon P Langdon, et al.
Molecular Cancer Research : MCR|September 10, 2009
Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivityYoko Nagumo, Dana Faratian, Peter Mullen, et al.
Pageof 5